NCT05630287View on ClinicalTrials.gov

A Study of Absorption, Metabolism, Excretion, and Absolute Bioavailability of Carbon-14-Labelled [14C] Selpercatinib (LY3527723) in Healthy Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 1, 2018

Primary Completion Date

September 24, 2018

Study Completion Date

September 24, 2018

Conditions
Healthy
Interventions
DRUG

[14C]-Selpercatinib

Administered as an oral solution

DRUG

Selpercatinib

Administered orally

DRUG

[14C]-Selpercatinib

Administered intravenously

Trial Locations (1)

53704

LabCorp CRU, Inc., Madison

Sponsors

Collaborators (1)

Loxo Oncology, Inc.
All Listed Sponsors
collaborator

Loxo Oncology, Inc.

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY

NCT05630287 - A Study of Absorption, Metabolism, Excretion, and Absolute Bioavailability of Carbon-14-Labelled [14C] Selpercatinib (LY3527723) in Healthy Male Participants | Biotech Hunter | Biotech Hunter